Stroke is a leading cause of death and disability. The only therapy available is recombinant tissue plasminogen activator, but side effects limit its use. Platelets play a crucial role during stroke, and the inflammatory reaction promotes neurodegeneration. von Willebrand factor (VWF), an adhesion molecule for platelets, is elevated in patients with acute stroke. The activity of VWF is modulated by ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats-13) that cleaves VWF to smaller less-active forms. We recently documented that ADAMTS13 negatively regulates both thrombosis and inflammation. We report that deficiency or reduction of VWF reduces infarct volume up to 2-fold after focal cerebral ischemia in mice, thus showing the importance of VWF in stroke injury. In contrast, ADAMTS13 deficiency results in larger infarctions, but only in mice that have VWF. Importantly, infusion of a high dose of recombinant human ADAMTS13 into a wild-type mouse immediately before reperfusion reduces infarct volume and improves functional outcome without producing cerebral hemorrhage.
IntroductionIschemic stroke is a leading cause of death and disability around the world. Each year in the United States approximately 795 000 persons have a new or recurrent stroke. 1 Thrombolytic therapy with tissue plasminogen activator (tPA), which leads to fibrin degradation and promotes clot lysis, is beneficial for ischemic stroke. 2,3 However, tPA use is restricted to the first few hours after stroke. In addition, tPA may increase the incidence and severity of cerebral hemorrhage and edema formation. 2,3 Thus, there remains a clear need to identify new therapeutic agents for minimizing the effects of stroke. In addition to their effect on coagulation, such agents could also target platelet adhesion and the inflammatory process that follows ischemic stroke.von Willebrand factor (VWF) is a large multimeric glycoprotein that is important in platelet adhesion and thrombus formation. 4 At least in mice, VWF appears more important in arterial thrombosis than fibrin, 5 the substrate of tPA/plasmin. More recently, VWF was also shown to contribute to leukocyte adhesion and inflammatory cell recruitment. 6,7 VWF is stored in an ultra-large form (UL-VWF; Ͼ 20 million kDa) in platelet ␣-granules and Weibel-Palade bodies of endothelial cells from which it is released during injury or inflammation. 8,9 If not immediately consumed for platelet adhesion, the UL-VWF is cleaved by ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats-13) to smaller less-adhesive multimers that circulate in plasma. ADAMTS13 is a metalloprotease of approximately 190 kDa 10 present in plasma at a concentration of 0.5 to1 g/mL in humans. 11 Ischemia is a potent inducer of Weibel-Palade body secretion, 12 thus making the infarct area highly thrombogenic even after thrombolysis.VWF deficiency is associated with the most common bleeding disorder in humans, von Willebrand disease. 13 In contrast, deficiency of ADAMTS13 is se...